Unibios Holdings S.A risk profile
46 Elevated one input has moved against it
Measured 1 September 2026 from BIOSK's filed statements. Recomputed nightly.
46 (Elevated), driven by Cash conversion at 92, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 43 | Elevated | Stable | One-year price volatility — 35.7% |
| Operating pressure | 50 | Elevated | Worsening | Costs outgrowing revenue — +4.8 percentage points |
| Cash conversion | 92 | Acute | Worsening | Capital spending against operating cash — 3.94x |
| Leverage and coverage | 25 | Normal | Easing | Interest cover — 9.45x |
| Competitive position | 40 | Elevated | Stable | R&D-intensity gap against peers — -4.2 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Industrials companies with a risk reading
Space Exploration Technologies Corp. 66Caterpillar Inc 41General Electric Company 29RTX Corp 38GE Vernova LLC 41Union Pacific Corp 35Deere & Company 42Rolls-Royce Holdings PLC 25Boeing Company 48Safran SA 32Eaton Corporation plc 35Hitachi, Ltd. 42
Financials, valuation and price history for Unibios Holdings S.A